Navigation Links
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Date:11/8/2007

with Gleevec-resistant chronic phase CML. A total of 670 patients (498 Gleevec resistant) were randomized to 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily. Those patients who received SPRYCEL once daily achieved a comparable (non-inferior) major cytogenetic response to those who received SPRYCEL twice daily. The rate of major cytogenetic response was lower among patients aged 65 years and over. The median duration of treatment was approximately eight months. The study supports the new recommended starting dose, 100 mg once daily, for chronic-phase CML.

Incidence of selected adverse reactions (all grades) in the Phase 3 dose- optimization study in chronic-phase CML patients receiving SPRYCEL 100 mg once daily (n=165) or SPRYCEL 70 mg twice daily (n=167) included diarrhea (23%, 25%); fluid retention events (24%, 32%) such as superficial edema (14%, 16%), pleural effusion (10%, 18%), generalized edema (2%, 1%), congestive heart failure/cardiac dysfunction (0%, 4%), pericardial effusion (1%, 2%), pulmonary edema (0%, 2%), pulmonary hypertension (0%, 1%), and hemorrhage (10%, 14%) including gastrointestinal bleeding (1%, 4%).

In this same study, the frequency of Grade 3/4 neutropenia, thrombocytopenia, and anemia was 34%, 22%, and 10%, respectively, in the SPRYCEL 100 mg once-daily group and 43%, 38%, and 17%, respectively, in the SPRYCEL 70 mg twice-daily group. The frequency of Grade 3/4 hypophosphatemia and hypocalcemia was 8% and 2%, respectively, in the SPRYCEL 100 mg once-daily group, and 7% and 2%, respectively, in the SPRYCEL 70 mg twice-daily group.

The starting dose for adults with accelerated-phase, myeloid or lymphoid blast-phase CML or adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to prior therapy remains at 70 mg twice daily.

SPRYCEL and Escalated Doses of Gleevec (Study -017): The Phase 2 randomized, open-label study evaluated SPRYCEL 70
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 The report ... & by Geography - Global Trends & Forecast ... with respect to market drivers, opportunities, and trends ... tables and 27 figures spread through 217 slides ... Global Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html ...
(Date:10/25/2014)... (PRWEB) October 23, 2014 ... specialty pharmaceutical company devoted to bringing new products ... in 2015. , ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
(Date:10/25/2014)... (PRWEB) October 23, 2014 BioProcess ... winners for the 2014 BioProcess International Awards. The ... social corporate responsibility and technology applications that will ... treatments to a global patient base. , Winners ... peers during a very entertaining and exciting awards ...
(Date:10/25/2014)... 2014 According to new market ... Center Types (Colocation, Enterprise, Telecom), by Design Types ... Tier 2, Tier 3, Tier 4) - Global ... segments the Data Center Construction Market into various ... revenues. This research report also identifies the factors ...
Breaking Biology Technology:Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... “What part of ... Barry Friedberg, MD. “Is the ASA not as smart as a fifth grader?” , ... (PRWEB) March 9, 2010 -- One ... relentless pursuit of patient safety ., , , , ,Yet no answer has been forthcoming ...
... ... ... ... ...
... ... Data-mining Platform Integrates a Variety of Data Streams into One Easy-to-use Analysis System ... (PRWEB) March 8, ... life science research, today announced Genedata Analyst™, an integrated statistical and data analysis platform ...
Cached Biology Technology:American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 2American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 2Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 4Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 5Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 6Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 2Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 3Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 4Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 5
(Date:10/25/2014)... , Oct.  22, 2014   MedNet Solutions ... clinical study management systems, is pleased to announce the ... two-day event – to be held in ... on track to have record attendance and promises to ... The focus of the meeting is ...
(Date:10/25/2014)... , Oct. 22, 2014 This report covers ... relatively new space in heavy pursuit of research due ... to miRNAs compared to other RNA components. miRNA,s non-coding ... a novel candidate for use as a biomarker for ... miRNA-based microarrays and diagnostics for the advancement in therapeutic ...
(Date:10/25/2014)... Oct. 22, 2014 A recent report, "Genetic ... the current and future genetic testing market. A comprehensive ... are covered in this report. On account of our ... and existing strengths and challenges; forecast for genetic testing ... likely to grow at a CAGR of around 9% ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... in the Sumatran jungle have captured first-time images of a ... into the elusive tiger,s behaviour. After a month in ... to record tigers in the Sumatran jungle caught the mother ... sniff and check out the camera trap. There are ...
... The volcanic eruptions thought responsible for Earth,s largest mass extinction ... animals 250 million years ago is still taking lives ... the first time, that the high silica content of coal ... substances in the coal to cause unusually high rates of ...
... A canine chromosome 7 locus that confers a high ... a collaboration between the Behavior Service at the Cummings ... at the University of Massachusetts Medical School and the ... findings are published in the January 2010 edition of ...
Cached Biology News:Camera traps yield first-time film of tigress and cubs 2Camera traps yield first-time film of tigress and cubs 3Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Tachykinin (H-2)...
...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.45 micron filtration, ... This formulation insures consistently high levels of ...
Biology Products: